Postpartum Depression (PPD): Market View

Postpartum Depression (PPD): Market View

Summary

This report provides a data-driven overview of the current and future competitive landscape in Postpartum Depression (PPD) Therapeutics.

In 2025, there were 10.89 million prevalent cases of PPD across the 16 countries covered in the analyst’s epidemiology forecast.

PPD is typically managed with psychotherapy (CBT or interpersonal therapy) and antidepressants, most commonly SSRIs, tailored to breastfeeding considerations and patient preferences, alongside practical supports such as sleep and family assistance. For moderate-to-severe illness, faster-acting neuroactive steroid treatments include IV brexanolone (a 60-hour monitored infusion) and oral zuranolone (a short-course regimen), although uptake may be constrained by cost, access, sedation, and logistical burden.

Patients with severe or high-risk features (suicidality, psychosis, or treatment-resistant symptoms) require urgent psychiatric evaluation and may need hospitalization and/or ECT.

The PPD pipeline includes 15 molecules, with no assets in the pre-registration stage, two in Phase III development, and seven in Phase II development.

Over the past decade, 159 clinical trials have been conducted in PPD. The year with the most studies initiated was 2024, with 24 trials, followed by 2021 with 23 trials. Additionally, 2022 saw the most Phase III trials initiated, with five.

Over the past decade, in deals involving companies developing PPD products, acquisitions accounted for the largest share of deals in North America (44.4%). By comparison, licensing agreements were most prevalent in Europe (40%) and partnerships in the Asia-Pacific region (50%). South America, along with the Middle East and Africa, had only asset transactions (100%).

The analyst survey results indicate SSRIs remain the preferred first-line therapy due to clinician familiarity and perceived effectiveness, while Zurzuvae (zuranolone) is generally positioned as a second-line option for SSRI non-responders and for patients requiring a rapid onset of benefit.

Scope

• The analyst’s PPD: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
• Components of the report include:
• - Disease Landscape
• - Disease Overview
• - Epidemiology Overview
• - Treatment Overview
• - Marketed Products Assessment
• - Breakdown by Mechanism of Action, Molecule type
• - Product Profiles with Sales Forecast
• - Pricing and Reimbursement Assessment
• - Annual Therapy Cost
• - Time to Pricing and Time to Reimbursement
• - Pipeline Assessment
• - Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• - Product Profiles with Sales Forecast
• - Late-to-mid-stage Pipeline Drugs
• - Phase Transition Success Rate and Likelihood of Approval
• - Clinical Trials Assessment
• - Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• - Enrolment Analytics, Site Analytics, Feasibility Analysis
• - Deals Landscape
• - Mergers, Acquisitions, and Strategic Alliances by Region
• - Overview of Recent Deals
• - Commercial Assessment
• - Key Market Players
• - Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Postpartum Depression (PPD) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Postpartum Depression (PPD) Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.